Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)

Clinical Trial ID NCT01708590

Rank	Title	Journal	Year	PubWeight™‹?›
1	The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing.	Nat Rev Immunol	2014	2.82
2	Antibodies to watch in 2014.	MAbs	2013	1.14
3	Antibodies to watch in 2013: Mid-year update.	MAbs	2013	1.13
4	Psoriasis.	Cold Spring Harb Perspect Med	2014	0.85
5	The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications.	Auto Immun Highlights	2014	0.83
6	Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials.	Dermatol Ther (Heidelb)	2016	0.83
7	A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis.	Dermatol Ther (Heidelb)	2015	0.82
8	Enigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of Arthritis.	Mediators Inflamm	2016	0.78
9	Clinical research (observations, pathophysiology & outcomes).	J Invest Dermatol	2015	0.75
10	Abstracts.	J Invest Dermatol	2015	0.75
11	Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective.	Dermatol Ther (Heidelb)	2016	0.75